Jagsonpal Pharmaceuticals
₹233.35
+0.15%
Delayed · cached 15 min
Fair value analysis
JAGSNPHARM
Jagsonpal Pharmaceuticals
₹232.99
Close used for this calculation
₹170.85Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
61/100
Quality radar
Consensus fair value
₹170.85
Above FV▼ -26.7% against the close used
Model range ₹81.30 – ₹246.59
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹81.30Fair value₹170.85Bull₹246.59
FairClose
52-week traded range
52W low ₹161.0752W high ₹250.10
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Jagsonpal Pharmaceuticals closed at ₹232.99, 36.4% above the consensus fair value of ₹170.85 drawn from 10 valuation models.
Financial DNA score 61/100 — Good. P/E of 32.7x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹141.51
-39.3%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=9%, r=10%, tg=3%, n=10yr
Graham Number
₹81.30
-65.1%
√(22.5 × EPS × BVPS)
EPS=6.43, BVPS=45.68 · outside Graham range (P/E 32.7, P/B 5.1) — asset-light, treat as a rough floor
Graham Formula
₹246.59
+5.8%
EPS × (8.5 + 2g) × 6.5 ÷ FD_Rate
g=16.4%, FD=7%
P/E Fair Value
₹229.55
-1.5%
EPS × 35.7x (sector P/E)
EPS=6.43, Sector P/E=35.7x
Peter Lynch (PEG)
₹105.45
-54.7%
EPS × Growth% (PEG = 1 is fair)
EPS=6.43, g=16.4%
EV/EBITDA
₹181.72
-22.0%
(EBITDA × 18x − Net Debt) ÷ Shares
EBITDA=670M
Dividend Discount (DDM)
₹216.40
-7.1%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=4.01, r=10%, g=8%
Book Value (P/B)
₹129.06
-44.6%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=45.68, ROE=17.3%, g=6%, r=10%
Reverse DCF
₹232.99
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 15.2% | Historical: 16.4%
Margin of Safety
₹131.05
-43.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=174.74, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.